

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gladwin *et al.*

Application No. 10/563,683

Filed: January 6, 2006

FILED VIA EFS

Confirmation No. 3225

For: USE OF NITRITE SALTS FOR THE
TREATMENT OF CARDIOVASCULAR
CONDITIONS

Examiner:

Art Unit:

Attorney Reference No. 4239-67618-07

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement (“IDS”) before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301
cc: Docketing

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630